Chiltern says strategic deals are good for the CRO sector

By Gareth Macdonald

- Last updated on GMT

Related tags Pharmacology Big pharma

Chiltern says that strategic partnering in the contract research sector enables CROs to plan for the longer term and is having a tangible impact on brining drugs to market. spoke with Aize Smink, Chiltern’s senior executive VP, global clinical development, who said that the drug industry’s need for efficiency is driving the formation of such deals.

He explained that these types of collaboration are not limited to Big Pharma, citing the UK-headquartered CROs agreement with a number of mid-sized drug makers as evidence.

“[Strategic partnering] allows us to focus on the long term and look at process improvement in a collaborative way with our pharma partners. So it also drives progress for CROs in that sense​.”

Related news

Show more

Related products

show more

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Content provided by Formedix | 17-Apr-2023 | White Paper

Companies often have to conduct multiple clinical trials at the same time, which means they've got to be efficient, and compliant with industry regulations....

Related suppliers

Follow us


View more